Omeprazole

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 40 mg delayed-release capsule fits only a narrow large-dog weight range and cannot be crushed or divided accurately. Twice-daily pre-feed administration is manageable when the dose matches, but most dogs need a lower-strength veterinary or validated compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 40 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human IV product has a sourced current Georgian registration and identifiable strength and manufacturer, but no accessible exact-product preparation dossier was found; route handling must not be copied from a comparator without verification. It has no veterinary authorisation.

Omeprazole has strong oral veterinary acid-suppression evidence and consensus support for selected ulcerative or reflux disease, but direct canine evidence for this IV formulation and route is absent. Human IV use supports temporary substitution when oral therapy is impossible; veterinary outcome benefit is inferred, not demonstrated.

The ingredient is generally well tolerated short term, but these exact human IV products lack canine target-animal safety data. Preparation errors, incompatibility, rapid administration, hepatic dysfunction, hypersensitivity and CYP/pH-dependent interactions require hospital control; unnecessary prolonged suppression adds rebound and microbiome risks.

A 40 mg vial can theoretically support weight-based hospital dosing, but an accessible exact-product reconstitution concentration, solvent, compatibility and in-use stability instruction was not found. Do not improvise from a comparator label; practicality remains limited until the exact instruction is verified.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human capsule has a sourced current Georgian registration and identifiable strength and manufacturer, but the EU/EEA, UK and US status remains explicitly unchecked rather than negative. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human capsule has a sourced current Georgian registration and identifiable strength and manufacturer, but the EU/EEA, UK and US status remains explicitly unchecked rather than negative. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human capsule has sourced current registrations in Georgia, EU/EEA and the UK, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human capsule has sourced current registrations in Georgia, EU/EEA and the UK, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 40 mg delayed-release capsule fits only a narrow large-dog weight range and cannot be crushed or divided accurately. Twice-daily pre-feed administration is manageable when the dose matches, but most dogs need a lower-strength veterinary or validated compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 40 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human capsule has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human capsule has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human capsule has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human capsule has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human capsule has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human capsule has sourced current registrations in Georgia and EU/EEA, with an identifiable manufacturer, strength and intact delayed-release form. It is not a veterinary-authorised presentation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human IV product has a sourced current Georgian registration, identifiable composition and manufacturer, and accessible exact-product preparation information corroborated by another official register. It has no veterinary authorisation and canine use is off-label.

Omeprazole has strong oral veterinary acid-suppression evidence and consensus support for selected ulcerative or reflux disease, but direct canine evidence for this IV formulation and route is absent. Human IV use supports temporary substitution when oral therapy is impossible; veterinary outcome benefit is inferred, not demonstrated.

The ingredient is generally well tolerated short term, but these exact human IV products lack canine target-animal safety data. Preparation errors, incompatibility, rapid administration, hepatic dysfunction, hypersensitivity and CYP/pH-dependent interactions require hospital control; unnecessary prolonged suppression adds rebound and microbiome risks.

The exact vial includes 10 mL solvent, yielding 4 mg/mL; this permits measurable canine dosing and is given slowly in hospital. It still requires aseptic reconstitution, exact-label compatibility, short in-use stability and disposal of substantial unused drug in small patients.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled canine studies show reliable acid suppression, superiority to famotidine and effective twice-daily 10 mg delayed-release capsules; a current authorised veterinary 10 mg capsule supports the class and formulation. Clinical outcome evidence is less extensive than pH evidence, and consensus rejects indiscriminate prophylaxis.

Short courses have a favourable, well-characterised profile and a current dog-authorised 10 mg comparator, but these exact human capsules lack canine dossiers. Prolonged use can cause hypergastrinaemia, rebound acid secretion and microbiome or nutrient effects; hepatic dysfunction, hypersensitivity and interactions require review.

This whole-only 20 mg delayed-release capsule can match selected medium or large dogs but cannot support small-dog or fine dose adjustment. Twice-daily administration before food is workable at home when the dose matches; do not crush or estimate unmeasured bead fractions.

The exact human presentation has a sourced current Georgian registration and identifiable manufacturer and strength, but exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It has no veterinary authorisation and animal use is off-label.

Controlled feline studies show that approximately 1 mg/kg twice daily suppresses gastric acid better than famotidine/placebo and peri-anaesthetic dosing raises gastric and oesophageal pH. Evidence is primarily physiologic and short-term rather than clinical healing outcomes, and routine prophylaxis is unsupported.

Short courses are generally tolerated, but exact human capsules lack a feline dossier. A 60-day study found hypergastrinaemia and rebound hyperacidity after withdrawal; prolonged suppression can alter flora and nutrient absorption, while hepatic dysfunction, hypersensitivity and clinically important interactions require review.

The studied feline dose is about 1 mg/kg twice daily, but this delayed-release capsule is whole-only at 20 mg and cannot accurately deliver the usual 4-6 mg dose. Crushing destroys gastro-resistance and unmeasured bead fractions are not validated; use a suitable veterinary or compounded form.